This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

News

09Jul 2019

Back to News overview

Marjanka Schmidt appointed professor

MarkankjaSchmidt.jpg

On April 1, 2019, group leader Marjanka Schmidt was appointed endowed professor in Leiden. Her chair at the Leiden University Medical Center is called "Genetic cancer epidemiology, in particular, breast cancer."

Marjanka Schmidt's research group is already working with colleagues in Leiden and is trying to find out which hereditary genetic variants predict the risk of, and the course of, breast cancer. Schmidt: "Everybody has heard of BRCA1 and BRCA2, but we now know that there are many more genes that are associated with breast cancer and possibly with the recurrence of the disease and therapy success." 

Gene panel

According to her, it is time to do more with that knowledge. "I want to understand how various genetic variants have an effect together. This information is important for the course of the disease and offers possibilities for prevention in healthy women with an increased risk of breast cancer. If someone comes in who already has breast cancer, or has a family member with breast cancer, we must inspect a lot more risk genes and test more on an individual level than we currently do. My first goal is to use such a multi-gene panel test in practice and to further investigate it." 

Expectation

The next step is to use the results of such a test to say something about the course of the disease. "This part of my work is still in its infancy, but ultimately we want to answer questions such as: which breast cancer subtype does someone develop and what can a patient expect from the course of the disease? Which treatment fits best? And how great is the risk of a second breast cancer or recurrence of the disease after treatment?" 

Share this page